Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
POLYMEDIX, INC (PYMX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/19/2012 GN PolyMedix Receives Grant From National Cancer Institute to Study Brilacidin for Oral Mucositis
09/11/2012 GN PolyMedix Presents New Data on Its Defensin-Mimetic Antibiotics at 52nd Annual ICAAC
09/05/2012 GN Data Showing Effectiveness of PolyCide Antimicrobial in Surgical Suture Coatings Published in American Chemical Society Journal, Langmuir
08/09/2012 GN PolyMedix Reports Second Quarter 2012 Financial Results
07/13/2012 GN PolyMedix Outlines Potential Benefits of GAIN Act to Its Antibiotic Development Program
06/12/2012 GN PolyMedix Receives USAN Approval for Generic Name of Brilacidin for PMX-30063
06/04/2012 GN New Data on PMX-30063 Presented at ASCO Suggest Strong Potential as Treatment for Oral Mucositis
05/10/2012 GN PolyMedix Provides Update on PMX-60056 Program
04/23/2012 GN PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic
04/20/2012 GN PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
04/10/2012 GN PolyMedix Restructures Its Debt and Secures $12 Million Credit Facility
03/05/2012 GN PolyMedix to Present at the Roth 24th Annual Growth Stock Conference
02/07/2012 GN PolyMedix to Present at the 14th Annual BIO CEO and Investor Conference
01/20/2012 GN PolyMedix Defensin-Mimetic Antimicrobial Compounds Show Activity Against Oral Candida Fungus and Malaria
12/07/2011 GN PolyMedix Announces Encouraging Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
12/06/2011 GN PolyMedix Launches New Website
10/24/2011 GN PolyMedix Presents PMX-30063 Antibiotic Data at the 49th Annual Meeting of the Infectious Disease Society of America
10/06/2011 GN PolyMedix Selected as Best Mid-Stage Product Development Company at Annual Life Sciences Awards
09/27/2011 GN PolyMedix Initiates Phase 1B/2 Dose-Response Clinical Trial to Reverse the Anticoagulant Activity of Enoxaparin with PMX-60056
09/19/2011 GN PolyMedix Presents Antibiotic Data in Oral Session at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
09/13/2011 GN PolyMedix to Present at the UBS Global Life Sciences Conference
09/12/2011 GN PolyMedix Provides Updates on Lead Clinical Programs
08/31/2011 GN PolyMedix Appoints Daniel M. Jorgensen, MD, MPH as Sr. Vice President, Clinical Development and Chief Medical Officer

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy